THE EFFECT OF CONTINUOUS SUBDERMAL LEVONORGESTREL (NORPLANT) ON CARBOHYDRATE-METABOLISM

被引:30
作者
KONJE, JC [1 ]
OTOLORIN, EO [1 ]
LADIPO, OA [1 ]
机构
[1] UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,FERTIL RES UNIT,WC1 LONDON,ENGLAND
关键词
NORPLANT; LEVONORGESTREL; PROGESTOGEN; CARBOHYDRATE METABOLISM;
D O I
10.1016/0002-9378(92)91819-V
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Blood glucose and plasma insulin levels during an oral glucose tolerance test were measured in 20 women using continuous subdermal levonorgestrel (Norplant) for contraception over a 12-month period. Changes in carbohydrate metabolism occurred as early as 1 month but were most marked after 6 months. After 1 month the area under the glucose and insulin curves increased by 12.3% and 37.7%, respectively. This increase was more marked by 6 months, but by 12 months it was significantly less marked. Although changes in the blood glucose and plasma insulin levels at different times during the oral glucose tolerance test occurred, they were all within normal limits for normal women. The peak blood glucose and insulin levels after insertion of the implant occurred 60 minutes after the glucose load, as opposed to 30 minutes before insertion. Apart from this, there was a significant delay in the return of these levels to fasting values. We conclude that this product, like any other progesterone-containing contraceptive, alters carbohydrate metabolism, but these alterations are not clinically significant in normal women. It is, however, possible that in potential cases of diabetes it may predispose to frank diabetes.
引用
收藏
页码:15 / 19
页数:5
相关论文
共 25 条
[1]   COMPARATIVE CLINICAL-TRIAL OF PROGESTINS-R-2323 AND LEVONORGESTREL ADMINISTERED BY SUBDERMAL IMPLANTS [J].
ALVAREZ, F ;
ROBERTSON, DN ;
MONTESDEOCA, V ;
SIVIN, I ;
BRACHE, V ;
FAUNDES, A .
CONTRACEPTION, 1978, 18 (02) :151-162
[2]   LEVONORGESTREL PLASMA-LEVELS DURING CONTINUOUS ADMINISTRATION WITH DIFFERENT MODELS OF SUBDERMAL IMPLANTS [J].
ALVAREZ, F ;
BRACHE, V ;
FAUNDES, A ;
JOHANSSON, EDB ;
ODLIND, V ;
NASH, H .
CONTRACEPTION, 1983, 27 (02) :123-130
[3]   CLINICAL-CHEMISTRY IN WOMEN TREATED WITH LEVONORGESTREL IMPLANTS (NORPLANT) OR A TCU-200 IUD [J].
CROXATTO, HB ;
DIAZ, S ;
ROBERTSON, DN ;
PAVEZ, M .
CONTRACEPTION, 1983, 27 (03) :281-288
[4]  
CROXATTO HB, 1978, CONTRACEPTION, V8, P441
[5]  
CROXATTO HB, 1985, CONTRACEPTION, V31, P321
[6]   A LONGITUDINAL-STUDY ON CORTISOL, PROLACTIN AND THYROID-HORMONES IN USERS OF NORPLANT SUBDERMAL IMPLANTS OR A COPPER-T DEVICE [J].
DIAZ, S ;
PAVEZ, M ;
BRANDEIS, A ;
CARDENAS, H ;
CROXATTO, HB .
CONTRACEPTION, 1989, 40 (04) :505-517
[7]   3-YEAR CLINICAL-TRIAL WITH LEVONORGESTREL SILASTIC IMPLANTS [J].
DIAZ, S ;
PAVEZ, M ;
ROBERTSON, DN ;
CROXATTO, HB .
CONTRACEPTION, 1979, 19 (06) :557-573
[8]  
GROSSAIN VV, 1983, AM J OBSTET GYNECOL, V147, P618
[9]   CHOLESTEROL AND HDL-CHOLESTEROL VALUES IN WOMEN DURING USE OF SUBDERMAL IMPLANTS RELEASING LEVONORGESTREL [J].
HOLMA, P ;
ROBERTSON, DN .
CONTRACEPTION, 1985, 32 (02) :163-171
[10]  
KALKHOFF RK, 1982, AM J OBSTET GYNECOL, V142, P735